The cost-effectiveness of bike lanes in New York City J Gu, B Mohit, PA Muennig Injury prevention 23 (4), 239-243, 2017 | 60 | 2017 |
Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update J Gu, RJ Sanchez, A Chauhan, S Fazio, ND Wong American journal of preventive cardiology 10, 100336, 2022 | 20 | 2022 |
Productivity growth of skilled nursing facilities in the treatment of post-acute-care-intensive conditions J Gu, N Sood, A Dunn, J Romley PloS one 14 (4), e0215876, 2019 | 10 | 2019 |
The association of vertically integrated care with health care use and outcomes PJ Huckfeldt, J Gu, JJ Escarce, P Karaca‐Mandic, N Sood Health services research 56 (5), 817-827, 2021 | 3 | 2021 |
The effects of accountable care organizations forming preferred skilled nursing facility networks on market share, patient composition, and outcomes J Gu, P Huckfeldt, N Sood Medical care 59 (4), 354-361, 2021 | 3 | 2021 |
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia J Gu, A Kuznik, P Quon, A Chauhan, TS Sravya, FJ Raal European Journal of Preventive Cardiology 30 (17), 1874-1880, 2023 | 2 | 2023 |
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease J Gu, RJ Sanchez, A Chauhan, S Fazio, RS Rosenson Journal of Clinical Lipidology 16 (6), 901-905, 2022 | 2 | 2022 |
PCN204 DO PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) RECEIVE TREATMENTS CONSISTENT WITH NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES AND WHAT ARE THE TOTAL … TM To, J Gu, J Li, M Schulz, AS Masaquel Value in Health 22, S94, 2019 | 2 | 2019 |
Value of germline multi-gene panel next generation sequencing (NGS) in identification of hereditary cancer syndromes (HCS) in colorectal cancer population (CRC). J Gu, C Ricker, A Barzi Journal of Clinical Oncology 36 (15_suppl), 1587-1587, 2018 | 2 | 2018 |
Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary J Gu, RN Gupta, H Cheng, Y Xu, FJ Raal European Journal of Preventive Cardiology, zwae144, 2024 | | 2024 |
A machine-learning algorithm using claims data to identify patients with homozygous familial hypercholesterolemia J Gu, M Epland, X Ma, J Park, RJ Sanchez, Y Li Scientific Reports 14 (1), 8890, 2024 | | 2024 |
Systematic review on the efficacy of current treatments for the management of homozygous familial hypercholesterolaemia R Gupta, H Cheng, J Gu, Y Xu, F Raal Atherosclerosis 379, S68, 2023 | | 2023 |
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH) J Gu, X Ma, M Epland, J Park, RJ Sanchez, Y Li Journal of Clinical Lipidology 17 (4), e24, 2023 | | 2023 |
PCN51 A COST-EFFCTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS AXITINIB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA J Gu Value in Health 23, S32, 2020 | | 2020 |
Productivity Growth of Skilled Nursing Facilities in Treating Post-Acute-Care-Intensive Conditions J Gu, JA Romley, N Sood Value in Health 21, S104, 2018 | | 2018 |